Core Insights - The Chilean government has awarded Beijing Sinovac Biotech Co., Ltd. (Sinovac) the exclusive supply contract for the 2026 flu vaccine, with over 8 million doses ordered [1] - This marks the second consecutive year that Sinovac has been the sole supplier for Chile's flu vaccine, indicating the company's product quality and international compliance capabilities are recognized by the Chilean public health system [1] - In 2025, Sinovac supplied over 8.3 million doses of flu vaccine in Chile, achieving an approximately 80% vaccination rate among the target population, which laid a solid foundation for the renewal of the contract [1] Collaboration and Research - Sinovac's collaboration with various partners in Chile has expanded from product supply to research cooperation and evidence building [2] - A multi-center clinical study on the quadrivalent flu vaccine, co-conducted by Sinovac and research partners from Chile and other countries, was published in the journal "Vaccines," confirming the vaccine's good immunogenicity and safety [2] - Another Phase III study evaluating both humoral and cellular immune responses in Chilean adults was published in "Nature Communications," further demonstrating the scientific basis for the good immunogenicity and safety of Sinovac's flu vaccine [2] Global Expansion - Sinovac's flu vaccine has been applied globally, entering nearly 20 countries and regions, with a cumulative supply of over 120 million doses, contributing to global flu prevention efforts [2]